On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now

Blog


Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH™ Drug Delivery Platform Proven to Enhance Absorption of Bioactive Compounds

  • DehydraTECH™ is patent protected for multiple Active Pharmaceutical Ingredients (APIs) including hemp oil CBD and cannabis, nicotine, non-steroidal anti-inflammatory drugs, and fat-soluble vitamins
  • Lexaria has 16 patents granted and over 60 patent applications pending worldwide
  • DehydraTECH™ shown to facilitate rapid uptake and highly targeted delivery of pharmaceuticals to the brain

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, is accelerating its patented DehydraTECH based drug delivery technology and formulation development. Funding received from the first tranche of Lexaria’s previously announced private placement of units, issued at a price of $0.45 per unit, realized gross proceeds of $699,410, which will be used to advance several company-wide goals (http://ibn.fm/hGP3x).

Earlier this year, Lexaria moved into its new head office that includes a Health Canada licensed research and development laboratory that is being used to conduct world-leading research into drug delivery methods and improvements. In addition to accelerating research in the company’s DehydraTECH drug delivery platform, Lexaria is also considering issuing a limited commercial release of DehydraTECH version 2.0, which has been shown to deliver 811% more CBD into animal blood than generic industry control formulations, the company stated in an update to shareholders (http://ibn.fm/cWL3T).

Lexaria’s focus on pioneering new technologies that can more efficiently deliver APIs into the bloodstream, where they can have their desired effect, includes developing an effective way to cross the blood-brain-barrier. Lexaria’s DehydraTECH version 2.0 is showing promise in this arena as testing indicated 1,937% more CBD reached animal brain tissue compared to generic industry control formulations.

Cannabidiol is emerging as a promising compound to treat or prevent movement disorders, such as those seen in Parkinson’s disease patients, according to an article published by the National Institutes of Health (http://ibn.fm/BTruO). Extending the range of drugs available for therapeutic use to treat neurological conditions such as Alzheimer’s and Parkinson’s disease is a critical area of study since there currently is no effective treatment for these diseases, according to an article in Physics World (http://ibn.fm/C3TcM).

Lexaria’s dedication to research and development can be seen in its strong and growing intellectual property portfolio. As of August 2019, the company’s patent portfolio includes approximately 60 patent applications filed and pending in more than 40 countries around the world, with 16 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally.

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

Last Tweets

Follow us: @Buy_Stocks_Now

From Our Blog

LiveWire Ergogenics Inc. (LVVV) Pioneers Potential Industry ‘Gold Standard’ with its 7X Pure Cannabis Compliance and Dosage Verification System

December 6, 2019

LiveWire collaborates with Basso Botanicals to launch new cannabis, cannabis/CBD dosage and verification system LVVV system improves transparency of cannabis industry by giving consumers, business, municipalities ability to verify product standards System makes it easier for growers, manufacturers and retailers to comply with increasingly strict industry requirements LiveWire Ergogenics Inc. (OTC: LVVV), a health and […]

Rotate your device 90° to view site.